Alys plans to conduct a phase 1/1b trial assessing the efficacy and safety of the mast cell selective c-Kit inhibitor in the CIndU subtype.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

Discover the future of regenerative skincare with Skin Moderne’s groundbreaking Exosomes Regenerative Complex, a plant-derived innovation led by Dr. Frank Roesken, MD, PhD.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

This review of the latest dermatologic studies includes insights into skin improvement with injectable hyaluronic acid, burden of chronic spontaneous urticaria, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

The JADE REAL study reported that flexible dosing of abrocitinib exhibited promise in patients with moderate to severe AD.

Researchers found CU was associated with increased odds of developing anxiety, depression, PTSD, and substance use disorder, among other conditions.

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Treatment with rupatadine led to improvements in CSU and chronic inducible urticaria.

Discover the revolutionary Hydrafacial HydraFillic with Pep9 Booster, enhancing skin hydration and reducing fine lines with advanced peptide technology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine-refractory CSU.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Raj Chovatiya, MD, PhD, MSCI, discussed his approach to personalizing treatment dosing plans with adult patients based on skin clearance and therapeutic type at RAD 2025.